Evaluating combined therapy with myoinositol and D-chiro-inositol in infertility management across PCOS phenotypes: a comprehensive retrospective data analysis
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20253523Keywords:
Polycystic ovary syndrome, Myoinositol, D-chiro-inositol, Infertility, PCOS phenotypes, Pregnancy ratesAbstract
Background: Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder affecting up to 20% of reproductive-aged women, often leading to infertility due to chronic anovulation. The condition has a multifactorial etiology involving genetic, hormonal, and metabolic factors, with insulin resistance being a key feature. The clinical presentation and therapeutic response can vary among different PCOS phenotypes. Myoinositol and D-chiro inositol has garnered attention as a potential insulin sensitizer with fertility-enhancing effects in women with PCOS. This study aimed to evaluate the impact of Myoinositol and D-chiro inositol treatment on fertility outcomes across different PCOS phenotypes, focusing on pregnancy rates and phenotype-specific responses.
Methods: A review of medical records from 200 women with PCOS treated at M2M Women’s Clinic between 2018 and 2020 was conducted. Each woman took a sachet twice daily containing 2 g of Myo-Inositol and 50 mg of D-Chiro-Inositol in a 40:1 ratio. They were grouped into four types (A, B, C, D) based on the Rotterdam criteria. Data on treatment specifics, fertility outcomes, and follow-up results were analysed, and Chi-square tests were employed to compare pregnancy rates across the phenotypes.
Results: Out of the 200 participants, 143 (71.5%) completed follow-up. The overall pregnancy rate was 70.6%, with rates of 70.4% in Phenotype A and 69.1% in Phenotype D. Phenotypes B and C achieved 100% conception rates; however, these findings were constrained by small sample sizes.
Conclusions: Myoinositol, in combination with D-Chiro-Inositol in the physiological 40:1 ratio, appears effective in improving fertility outcomes, particularly in Phenotypes A and D. Further research with larger sample sizes is warranted to validate these findings across all PCOS phenotypes and refine phenotype-specific treatment protocols.
Metrics
References
Singh S, Gori P, Patel P, Paul A. Comprehensive Overview of PCOS: exploring etiology, diagnosis, and treatment approaches. Curr Pharmacol Rep. 2025;11(39). DOI: https://doi.org/10.1007/s40495-025-00419-w
Ganie MA, Chowdhury S, Malhotra N, Sahay R, Bhattacharya PK, Agrawal S, et al. Prevalence, phenotypes, and comorbidities of polycystic ovary syndrome among Indian women. JAMA Network Open. 2024;7(10):e2440583-.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. DOI: https://doi.org/10.1016/j.fertnstert.2003.10.004
Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler JE. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647-58. DOI: https://doi.org/10.1530/EC-17-0243
Fitz V, Graca S, Mahalingaiah S, Liu J, Lai L, Butt A, et al. Inositol for Polycystic Ovary Syndrome: a systematic review and meta-analysis to inform the 2023 update of the International Evidence-based PCOS Guidelines. J Clin Endocrinol Metab. 2024;109(6):1630-55. DOI: https://doi.org/10.1210/clinem/dgad762
Greff D, Juhász AE, Váncsa S, Váradi A, Sipos Z, Szinte J, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023;21(1):10. DOI: https://doi.org/10.1186/s12958-023-01055-z
Zheng X, Lin D, Zhang Y, Lin Y, Song J, Li S, et al. Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine (Baltimore). 2017;96(49):e8842. DOI: https://doi.org/10.1097/MD.0000000000008842
Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Treatment with myo-inositol does not improve the clinical features in all PCOS phenotypes. Medicines (Basel). 2023;11(6):1759. DOI: https://doi.org/10.3390/biomedicines11061759
Zhang J, Zhang H, Zhou W, Jiang M, Lin X. Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025;16:1498372. DOI: https://doi.org/10.3389/fendo.2025.1520362
Downloads
Published
How to Cite
Issue
Section
